About zolbetuximab
Claudin 18.2-targeted monoclonal antibody
Used for
- With chemotherapy for adults with advanced HER2-negative stomach or gastroesophageal junction cancer that tests positive for CLDN18.2.
Usual adult dose
800 mg/m² IV for the first dose, then 600 mg/m² every three weeks; alternatively, 800 mg/m² every four weeks. Given with chemotherapy.
Common side effects
- Nausea and vomiting
- Infusion-related reactions
- Reduced appetite
- Low blood-cell counts, including neutropenia
Important warnings
- Administer by infusion in a monitored clinical setting; serious infusion reactions can occur.
- Premedication and anti-nausea treatment are generally needed.
- Use only for tumors confirmed positive for CLDN18.2 and negative for HER2.
- Treatment may be delayed or stopped for severe reactions or toxicity.
Pregnancy
May harm a fetus; pregnancy status should be checked before treatment. Avoid pregnancy during treatment and for six months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for six months after the last dose.
Interactions
- No established clinically important drug interactions; combination chemotherapy can increase overlapping side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.